Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
Marjolein M van VlietCheryl J HendricksonBrooke E NicholsCharles Ab BoucherRemco P H PetersDavid van de VijverPublished in: Journal of the International AIDS Society (2020)
Providing long-acting PrEP to injectable contraceptive users in Limpopo is only potentially cost-effective when long-acting PrEP drug prices are low. If low prices are not feasible, providing long-acting PrEP only to women at high risk of HIV infection will become important.